Citius Pharmaceuticals (NASDAQ: CTXR) is making notable strides in its transition from a development-stage biotech to a commercial-stage company, driven by the FDA-approved targeted immunotherapy LYMPHIR (denileukin diftitox-cxdl). The company reported that LYMPHIR generated $5.6 million in net product revenue during the first six months of fiscal 2026, following its commercial launch in December 2025. With gross margins of approximately 80%, the therapy has achieved nearly 100% payer coverage of covered commercial lives, and 83% of targeted accounts had secured formulary inclusion or were under active review as of May 2026. This initial commercial success provides Citius with a revenue-generating oncology asset and a foundation for future growth.
LYMPHIR is approved for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. CTCL is a rare form of non-Hodgkin lymphoma that affects the skin. The therapy is an engineered fusion protein combining interleukin-2 and diphtheria toxin, designed to target cells expressing IL-2 receptors. Beyond the initial U.S. launch, Citius Oncology announced an initial shipment of LYMPHIR to Europe in April 2026, signaling early international expansion. The company also reported repeat orders from initial accounts, indicating growing physician adoption.
Citius is exploring LYMPHIR's potential in additional oncology settings. Investigator-initiated studies evaluated LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic cancers and prior to commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma. Positive topline results from both Phase 1 studies were reported in fiscal 2026, suggesting broader applicability of the therapy.
Beyond LYMPHIR, Citius's pipeline includes Mino-Lok, a late-stage antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections (CRBSIs) and central line-associated bloodstream infections (CLABSIs). These infections are particularly serious in cancer and hemodialysis patients who rely on central venous catheters for treatment. Mino-Lok aims to eradicate infection while preserving the catheter, avoiding the risks of removal and reinsertion, such as pneumothorax, arterial puncture, and catheter misplacement. Currently, there are no FDA-approved therapies specifically indicated for salvaging infected central venous catheters. Mino-Lok met its primary and secondary endpoints in a pivotal Phase 3 superiority trial and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA. The company holds worldwide rights through a license from The University of Texas MD Anderson Cancer Center. Following a Type C meeting with the FDA, Citius received guidance outlining a pathway to support a future New Drug Application submission. Investor materials estimate worldwide sales potential of approximately $1.8 billion for Mino-Lok.
Another pipeline candidate, Halo-Lido (CITI-002), is a proprietary topical formulation combining halobetasol and lidocaine for the symptomatic treatment of hemorrhoids. With an estimated 10 million people in the U.S. reporting hemorrhoid symptoms annually, and no FDA-approved prescription products currently available for this indication, Halo-Lido could become the first if approved. The company completed a Phase 2b study in 2023 and has met with the FDA to discuss next steps.
Citius is also developing a stem cell platform based on induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) for acute respiratory distress syndrome (ARDS), including lung injury associated with sepsis. Interim results from a proof-of-concept sheep model showed improvements in oxygenation, systemic shock, pulmonary vascular injury, and bacterial clearance compared with controls. Additional studies are planned to inform future human trials.
The company's leadership team brings extensive pharmaceutical experience. Leonard Mazur, Co-Founder, CEO, and Chairman, has around five decades in the industry, having previously founded Genesis Pharmaceuticals and co-founded Akrimax Pharmaceuticals. Myron Holubiak, Co-Founder and Executive Vice Chairman, served as president of Roche Laboratories and held multiple sales and marketing roles during a 19-year career there. This experience supports Citius's strategy to advance differentiated therapies from development to commercialization.
With LYMPHIR now generating commercial revenue and a diversified pipeline addressing significant unmet medical needs, Citius is positioned for multiple potential catalysts. The company's focus on critical care indications and its progress in both commercial and clinical stages underscore its potential impact on patients and the biopharmaceutical industry.
